Google expands its interest in the wearable device space.
Google has agreed to acquire Fitbit for $2.1 billion in cash.
Fitbit health and wellness data will not be used for Google ads, according to a press release.
Fitbit’s fitness trackers monitor users’ daily steps, calories burned, and distance traveled. They also measure floors climbed, sleep duration, and quality, and heart rate.
“Google is an ideal partner to advance our mission. With Google’s resources and global platform, Fitbit will be able to accelerate innovation in the wearables category, scale faster, and make health even more accessible to everyone. I could not be more excited for what lies ahead,” James Park, co-founder and CEO of Fitbit said the release. “Google is an ideal partner to advance our mission. With Google’s resources and global platform, Fitbit will be able to accelerate innovation in the wearables category, scale faster, and make health even more accessible to everyone. I could not be more excited for what lies ahead.”
Related: The Future Of Healthcare Wearables
However, Vik Panda, North America managing director for Dreem, a sleep health company located in Paris, New York and Taipei, cautions that wearables and trackers without solutions have demonstrated limited value.
“In sleep health for instance, trackers are not recommended by sleep specialists because they are not using methods that are proven to work,” Panda says. “Monitoring sleep requires looking at the whole picture, including brain health, not just your heart rate and movement. Quick fixes via pills or gadgets should not be a replacement for traditional clinical practice. Google, Fitbit, Apple, or Amazon should be incorporating technology that builds on traditional medical practices, and offer solutions that are proven to work.”
According to Panda, companies like Google need to offer healthcare technology that includes programs shown to result in behavioral changes. “Gadgets can help, but only when they support real behavioral science based on what has been proven to work in the medical community,” he says. “If we see behavioral therapists being hired, and if we see them having partnerships with technology that works, then we will take more notice.”
Fitbit has sold more than 100 million devices and supports an engaged global community of millions of active users, utilizing data to deliver personalized guidance and coaching to its users. Fitbit will continue to remain platform-agnostic across both Android and iOS.
The transaction is expected to close in 2020, subject to customary closing conditions, including approval by Fitbit’s stockholders and regulatory approvals.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More